Drug Trial Radar · NCT06364631
CARE1 Pragmatic Clinical Trial
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,250
Planned (sponsor's estimate)
Start
Apr 12, 2024
Primary completion
May 5, 2032
Study completion May 5, 2032
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission; CRIS Cancer Foundation; National Cancer Institute, France; Rennes University Hospital; University Hospital, Essen; Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron; The Netherlands Cancer Institute; Servicio Madrileño de Salud, Madrid, Spain; Hospital Universitario 12 de Octubre; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Medical University of Vienna; FAKULTNI NEMOCNICE OLOMOUC; International Kidney Cancer Coalition; Association pour la Recherche sur les Tumeurs du Rein; Resilience; PRIMAA; Queen Mary University of London
- First posted
- Apr 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD1/PDL1 axis or CTLA4. Combination therapy is SOC for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the 2 approaches and patients are treated based on physician decision without clinical /biomarker factors to guide treatment selection. PDL1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PDL1(+) and ICI-VEGFR TKI in PDL1(-) patients. Study design has been developed to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging Overall Survival (OS) for PDL1(+) patients and to demonstrate that ICI-VEGFR TKI is superior to ICI-ICI in prolonging Progression Free Survival (PFS) and OS for PDL1(-) patients.
Conditions
- Metastatic Kidney Cancer
- Metastatic Kidney Carcinoma
Interventions
NivolumabDrug
Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.
IpilimumabDrug
The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion. When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle.
PembrolizumabDrug
Pembrolizumab is to be administered as an approximately 30-minute IV infusion.
CabozantinibDrug
Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
AxitinibDrug
Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.
LenvatinibDrug
Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS).Time frame: At end of study, 97 months
Locations
46 sites in 4 countries. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria · Not yet recruiting
Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU)
Brno, Czechia · Not yet recruiting
Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK)
Hradec Králové, Czechia · Not yet recruiting
Fakultní nemocnice Olomouc, University Hospital Olomouc (FNOL)
Olomouc, Czechia · Recruiting
Fakultní nemocnice v Motole, University Hospital Motol (MOTOL)
Prague, Czechia · Not yet recruiting
Institut de Cancérologie de l'Ouest - Angers
Angers, France · Recruiting
CHU Angers
Angers, France · Recruiting
Institut Sainte Catherine
Avignon, France · Recruiting
CH de la Côte Basque
Bayonne, France · Recruiting
Hôpital Jean Minjoz
Besançon, France · Recruiting
CHU de Bordeaux Hôpital Saint-André
Bordeaux, France · Not yet recruiting
Centre François Baclesse
Caen, France · Recruiting
CH Châlon Sur Saône
Chalon-sur-Saône, France · Not yet recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Not yet recruiting
Hôpital Henri Mondor
Créteil, France · Recruiting
Centre Georges-François Leclerc
Dijon, France · Recruiting
CHU Grenoble
Grenoble, France · Recruiting
CHD Vendée
La Roche-sur-Yon, France · Recruiting
Centre Oscar Lambret
Lille, France · Not yet recruiting
Polyclinique de Limoges
Limoges, France · Recruiting
Centre Léon Bérard
Lyon, France · Not yet recruiting
Institut Paoli-Calmettes
Marseille, France · Recruiting
Institut Régional du Cancer de Montpellier
Montpellier, France · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
CHU de Nîmes
Nîmes, France · Recruiting
Hôpital de la Pitié Salpêtrière
Paris, France · Not yet recruiting
Hôpital Bichat - Claude Bernard
Paris, France · Not yet recruiting
Hôpital Tenon
Paris, France · Recruiting
Hôpital Saint-Louis
Paris, France · Recruiting
Institut Mutualiste Montsouris
Paris, France · Recruiting
CH de Pau
Pau, France · Recruiting
Hospices Civils de Lyon
Pierre-Bénite, France · Recruiting
CHU Poitiers
Poitiers, France · Recruiting
Institut Godinot
Reims, France · Recruiting
Centre Eugène Marquis
Rennes, France · Recruiting
CHU Saint-Etienne
Saint-Etienne, France · Not yet recruiting
Institut de Cancérologie de l'Ouest - Saint Herblain
Saint-Herblain, France · Recruiting
HIA Bégin
Saint-Mandé, France · Recruiting
CHU Sud Réunion
Saint-Pierre, France · Recruiting
Institut de cancérologie Strasbourg Europe
Strasbourg, France · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.